Skip to content

RESEARCH LITERACY / SOURCE NOTES

CJC-1295 DAC versus “no DAC”: what needs checking?

The long-acting CJC-1295 in the cited research includes an albumin-binding design. Do not apply its pharmacokinetics to something labelled “no DAC” without verifying exactly which molecule is described.

Editorial draft · primary sources linked; not independently clinically reviewed.
Editorial update:

Keep the modification with the name

Preclinical work describes GRF analogues designed to bind albumin. The subsequent healthy-adult study concerns the long-acting CJC-1295 preparation, not every GRF-related product.

What the human research measured

The healthy-adult trials examined hormone responses and tolerability over limited observation periods. Changes in GH or IGF-I are not proof of improved recovery, body composition or long-term clinical outcomes.

How to read “no DAC” or “modified GRF”

Treat those as labels that need a defined sequence and modification statement. Ask whether the material has the albumin-binding modification, and whether the cited study tested that exact material.

A market name, a matching short sequence label or an alias in a database is not enough to make two preparations interchangeable. We do not assign a precise half-life to an unverified preparation.

Do not reverse-engineer a schedule

A long-acting trial cannot supply a dosing frequency for a different preparation. This comparison explains identity and evidence transfer; it does not give a combined secretagogue protocol.

If a profile or report leaves the modification unclear, keep that limitation in the summary and return to the original laboratory or study record.

All evidence guides →